Question · Q3 2025
Joshua Chazaro asked about the basis for BioNTech's decision to advance pumitamig into gastric cancer, specifically whether it was driven by compelling clinical data (and if such data was presented) or primarily by an understanding of the mechanism of action.
Answer
Uğur Şahin, Chief Executive Officer and Co-founder, stated that the decision is based on emerging data for pumitamig in gastric cancer, an indication where checkpoint blockade is approved and responses have been observed in combination with chemotherapy. He noted that based on data from other GI indications, there is clear room for improving over standard of care, and the mechanistic rationale of anti-angiogenic and PD-1 targeting approaches is validated in gastric cancer.